Nerve Blocks in Alloplastic Breast Reconstruction
Launched by UNIVERSITY OF BRITISH COLUMBIA · Apr 22, 2021
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different types of nerve blocks can help manage pain for women undergoing mastectomy (breast removal) followed by immediate breast reconstruction. The researchers want to find out if a specific combination of local anesthesia (numbing medicine) used during surgery can lead to less pain afterward, lower the need for opioid painkillers, and improve recovery experiences. This study is important because managing pain effectively can help patients heal better and feel more comfortable after surgery.
To participate in this trial, women must be at least 19 years old and classified as ASA grade I or II, meaning they are generally healthy or have mild health issues. They should be having a total mastectomy with immediate reconstruction using a tissue expander or implant. However, certain people are not eligible, including those with specific health conditions or those who are pregnant. If you join the study, you can expect to receive care focused on pain management and recovery, and you'll be closely monitored to see how well the treatments work.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients must be female, and at least 19 years old.
- • 2. Patients must be ASA grade I or II.
- • 3. Patients must be undergoing total mastectomy with IBR using tissue expander or implant, with or without axillary surgery.
- Exclusion Criteria:
- • 1. Patients have a known contraindication for a regional block: known coagulation disorder, treatment with anticoagulants, infection at the injection site, known allergy to medication in the study.
- • 2. Patients who are pregnant at the time of surgery.
- • 3. Patients having bilateral mastectomy and immediate alloplastic breast reconstruction (as only one side can be blocked to prevent local anesthesia toxicity).
- • 4. Patients with ASA Class III or IV.
- • 5. Patients with BMI\>35kg/m2.
- • 6. Patients weighing less than 50kg.
- • 7. Patients living/staying outside of 1-hour driving distance from hospital.
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Kathryn Isaac, MD MPH FRCSC
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials